The Medical Letter on Drugs and Therapeutics
Once-Daily Gabapentin (Gralise) for Postherpetic Neuralgia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

A new once-daily formulation of gabapentin (Gralise – Depomed) has been approved by the FDA for treatment of postherpetic neuralgia (PHN). Immediate-release (IR) gabapentin (Neurontin, and others), which has been available in the US since 1994, is also approved for this indication, but is taken three times a day. Extended-release gabapentin enacarbil (Horizant) was recently approved by the FDA for treatment of restless legs syndrome.1

MECHANISM OF ACTION — Gabapentin is a structural analog of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). Its mechanism of action in relieving pain may be due to modulation of the alpha2delta subunit of voltage-gated calcium channels. Gralise is a gastroretentive tablet; it swells in gastric fluid and remains in the upper gastrointestinal tract, gradually releasing gabapentin over about ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Once-Daily Gabapentin (Gralise) for Postherpetic Neuralgia
Article code: 1378b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian